Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Gilead Sciences

Status and phase: Enrolling; Phase 2

Conditions: Cutaneous Lupus Erythematosus (CLE)

Treatments: Drug: Edecesertib; Drug: Edecesertib Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT05629208

2022-501523-24 (Other Identifier)

GS-US-497-6486

Details and patient eligibility

About

The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.

Enrollment: 33 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Either fulfill European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 classification criteria for systemic lupus erythematosus (SLE) and/or have biopsy confirmed Cutaneous Lupus Erythematosus (CLE) at any time.

• Must have active CLE at screening and Day 1. Individuals with acute CLE (ACLE) must have involvement of 2 distinct body areas.

• Cutaneous Lupus Erythematosus Disease Area and Severity Index activity - A (CLASI-A) score (excluding alopecia) of ≥ 8 and CLASI-A erythema score of ≥ 4 during screening and on Day 1. Individuals with SLE must have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥ 4 at screening.

• Presence of at least 1 representative lupus skin lesion amenable to punch biopsy and individual willingness to undergo skin punch biopsy at 2 time points.

• Must have documented prior intolerance or inadequate response at any time (per investigator judgement) to protocol-specified treatments.

  • Topical corticosteroids or topical calcineurin inhibitors.
  • Oral corticosteroids.
  • Any other nonbiologic standard-of-care therapy, including, but not limited to: chloroquine, quinacrine, hydroxychloroquine, azathioprine, mycophenolate mofetil (MMF), leflunomide, dapsone, or methotrexate (MTX).

• Individuals willing to comply with all study visits and assessments.

Key Exclusion Criteria:

• Individuals with only chilblains lupus, lupus panniculitis, lupus tumidus and/or localized acute CLE involving only 1 distinct body area at screening and Day 1.

• Have highly active SLE (including but not limited to lupus nephritis, neuropsychiatric SLE, and/or vasculitis).

• Presence of active skin conditions other than cutaneous lupus that may interfere with assessing lupus-specific skin lesion(s) (eg, psoriasis, and/or drug-induced lupus).

• Meet protocol-specified infection or lab criteria.

  • Any active infection that is clinically significant (per investigator judgment).

• Any history of clinically significant liver disease.

• Significant cardiovascular disease.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

33 participants in 2 patient groups, including a placebo group

Edecesertib

Experimental group

Description:

Participants will receive edecesertib 30 mg, once daily starting on Day 1 for up to 12 weeks.

Treatment:

Drug: Edecesertib

Edecesertib Placebo

Placebo Comparator group

Description:

Participants will receive edecesertib placebo, once daily starting on Day 1 for up to 12 weeks.

Treatment:

Drug: Edecesertib Placebo